ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Charles River Buys Contract Researcher

by Michael McCoy
March 17, 2014 | APPEARED IN VOLUME 92, ISSUE 11

Charles River Laboratories has signed an agreement to buy the contract research division of the Belgian drugmaker Galapagos for about $179 million. The division includes Argenta and BioFocus, companies that together had sales last year of $87 million. The two companies employ more than 340 scientists, many of whom are chemists, at sites in England and the Netherlands. For Galapagos, the sale will end a strategy of combining internal drug discovery and contract research services. For Charles River, the purchase will add in vitro capabilities to its current in vivo expertise.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment